ÂÜÀòÂÒÂ×

Dr. Westin lead the antimitotic group and was promoted to Vice President & Head of Early Clinical Research and Development in the Oncology Therapeutic Area Unit. As the lead for that group he worked closely with both research and business development to help refine strategy for the shift in portfolio biology toward targeted therapy and immuno-oncology. In 2017, Dr. Westin joined ImmunoGen and is currently Vice President of Clinical Development and Translational Sciences.